[Myalgia-hypereosinophilia syndrome caused by L-tryptophan].
Lacour
J P
JP
Service de Dermatologie, Hôpital Pasteur, Nice.
Ortonne
J P
JP
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D002487:Centers for Disease Control and Prevention, U.S.; D004802:Eosinophilia / Q000139:chemically induced* / Q000188:drug therapy; D006801:Humans; D009135:Muscular Diseases / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D009422:Nervous System Diseases / Q000139:chemically induced; D010146:Pain / Q000139:chemically induced* / Q000188:drug therapy; D011537:Pruritus / Q000139:chemically induced; D012595:Scleroderma, Systemic / Q000139:chemically induced; D013577:Syndrome; D014364:Tryptophan / Q000009:adverse effects* / Q000378:metabolism; D014481:United States
D000305:Adrenal Cortex Hormones; D014364:Tryptophan
Syndrome myalgies-hyperéosinophilie lié au L-tryptophanne.